Full Breakdown
Trump Proposes Executive Board to Direct NIH Grants
By Drooid · · How we work
Trump Proposes Executive Board to Direct NIH Grants
On September 20, 2026, President Donald Trump instructed his budget director, Russ Vought, to draft an executive order that would create a new board to decide which grants the National Institutes of Health (NIH) receives. The board, as described in the report, would be composed of NIH Director Jay Bhattacharya, Vought—who also heads the White House Office of Management and Budget—and would be required to reach unanimous decisions on all award allocations. This structure would give Vought a direct role in allocating the agency’s congressionally appropriated funds.
Recent Cuts to Federal Health Research Funding
The proposal emerges after the administration implemented research-funding reductions last year, targeting federal spending at major universities. Those cuts led to the freezing or cancellation of grants at numerous institutions, prompting criticism from the scientific community. The Trump administration has defended the reductions, arguing they are needed to ensure that federal money supports “solid science” and to reverse what it calls years of misguided funding priorities.
Principal Figures Involved
- Donald Trump – President of the United States, initiating the executive-order plan.
- Russ Vought – Director of the White House Office of Management and Budget and the administration’s budget director, tasked with drafting the order.
- Jay Bhattacharya – Director of the National Institutes of Health, slated to serve on the proposed grant-review board.
Anticipated Effects on Scientific Grants
If enacted, the board’s unanimity requirement could concentrate decision-making authority among a small group of political appointees, potentially reshaping which research projects receive federal support. Critics fear that such a model may prioritize politically favored topics over independent scientific merit, while the administration maintains the change will safeguard taxpayer dollars and focus funding on research it deems reliable. The ultimate impact on the nation’s health-research enterprise will depend on how the board interprets “solid science” and applies its unanimous-vote rule.